Osanetant

Osanetant
Clinical data

ATC code	none
Identifiers
IUPAC name N-(1-{3-[(3R)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl}-4-phenylpiperidin-4-yl]-N-methylacetamide
CAS Number	160492-56-8^Y
PubChem CID	219077
IUPHAR/BPS	2110
ChemSpider	189901^N
UNII	K7G81N94DT
ChEMBL	CHEMBL346178^N
ECHA InfoCard	100.233.307
Chemical and physical data
Formula	C₃₅H₄₁Cl₂N₃O₂
Molar mass	606.625 g/mol
3D model (Jmol)	Interactive image
SMILES CC(=O)N(C)C1(CCN(CC1)CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl)C5=CC=CC=C5
InChI InChI=1S/C35H41Cl2N3O2/c1-27(41)38(2)35(29-13-7-4-8-14-29)19-23-39(24-20-35)21-9-17-34(30-15-16-31(36)32(37)25-30)18-10-22-40(26-34)33(42)28-11-5-3-6-12-28/h3-8,11-16,25H,9-10,17-24,26H2,1-2H3/t34-/m0/s1^N Key:DZOJBGLFWINFBF-UMSFTDKQSA-N^N
^NY (what is this?)

Osanetant (SR-142,801) was a neurokinin 3 receptor antagonist developed by Sanofi-Synthélabo, which was being researched for the treatment of schizophrenia, but was discontinued. It was the first non-peptide NK₃ antagonist developed in the mid-1990s, Other potential applications for osanetant is in the treatment of drug addiction, as it has been found to block the effects of cocaine in animal models.

...
Wikipedia